Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
WEB3 days ago · September 19, 2024 — 10:21 am EDT. Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory ...
FDA Approves Pembrolizumab With Chemotherapy for …
WEB4 days ago · On September 17, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma.
Keytruda Plus Chemo Approved for Malignant Pleural Mesothelioma
WEB3 days ago · The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.
FDA Approves Pembrolizumab with Chemotherapy for …
WEB3 days ago · On 17 September 2024, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
FDA approves pembrolizumab with chemotherapy for …
WEB5 days ago · Patients were randomized (1:1) to receive either pembrolizumab for up to 2 years in combination with pemetrexed and platinum-based chemotherapy for up to 6 cycles (n=222) or pemetrexed and ...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEB4 days ago · RAHWAY, N.J., September 18, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck ...
FDA Approves Pembrolizumab/Chemo in Unresectable Pleural Mesothelioma
WEB5 days ago · A treatment regimen consisting of pembrolizumab (Keytruda) plus pemetrexed and platinum-based chemotherapy has earned FDA approval as a first-line therapy for patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM), according to a press release from the agency. 1 The regulatory agency approved pembrolizumab at a recommended dose of 200 mg every 3 weeks or …
FDA Approves Pembrolizumab-Chemo Regimen for Advanced Mesothelioma
WEB4 days ago · The FDA approved frontline pembrolizumab plus pemetrexed and platinum-based chemotherapy for the treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Pembrolizumab Approved With Chemotherapy for MPM
WEB3 days ago · Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM) in ...
Mesothelioma Newest Approved Indication for Pembrolizumab
WEB4 days ago · The FDA approved pembrolizumab (Keytruda; Merck) with chemotherapy as a first-line treatment for advanced or metastatic malignant pleural mesothelioma (MPM) that cannot be removed with surgery. In KEYNOTE-483, a phase II/III, open-label trial whose results were presented in 2023, patients with no prior systemic therapy for advanced or metastatic MPM received either pembrolizumab for up to 2 ...